Immunological basis for IgE hyper-production in enfuvirtide-treated HIV-positive patients

Journal of Clinical Immunology

Volumn 26, Issue 2, 2006, Pages 168-176

  Burastero, Samuele E ^a   Paolucci, Clara ^a   Breda, Daniela ^a   Soldarini, Armando ^b   Dorigatti, Fernanda ^b   Soprana, Elisa ^a   Hasson, Hamid ^a   Biswas, Priscilla ^a   Lazzarin, Adriano ^a   Castagna, Antonella ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Laboraf Diagnostica e Ricerca   (Italy)

Author keywords

B lymphocytes; Enfuvirtide (ENF); IFN ; Ig switch; IgE, Th1; IL 4; Immunological response; T lymphocytes; Th2

Indexed keywords

CD4 ANTIGEN; ENFUVIRTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 4;

ARTICLE; B LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG HYPERSENSITIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; INTERFERON PRODUCTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TH2 CELL;

ANTI-HIV AGENTS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN E; PEPTIDE FRAGMENTS; TH2 CELLS;

EID: 33745007159     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-006-9005-7     Document Type: Article

References (36)

1. Moore JP, Doms RW: The entry of entry inhibitors: A fusion of science and medicine. Proc Natl Acad Sci USA 100:10598-10602, 2003
2. Castagna A, Biswas P, Beretta A, Lazzarin A: From discovery of biological mechanisms to drug development: the appealing history of drug inhibitors. Drugs 65: 879-904, 2005
3. Cervia JS, Smith MA: Enfuvirtide (T-20): A novel human immunodeficiency virus type 1 fusion inhibitor. Clin Infect Dis 37:1102-1106, 2003
4. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D: Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 3:215-225, 2004
5. Asboe D: Enfuvirtide: Antiretroviral class 4, drug 1. HIV Clin Trials 5:1-6, 2004
6. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Jr., Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175-2185, 2003
7. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348:2186-2195, 2003
8. Myers SA, Selim A, McDaniel M: A prospective clinical and histological examination of infection sites with the fusion inhibitor enfuvirtide (ENF). Fortythird Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago (USA), 2003: Abstract H-2015
9. Fung HB, Guo Y: Enfuvirtide: A fusion inhibitor for the treatment of HIV infection. Clin Ther 26:352-378, 2004
10. Hardy H, Skolnik PR: Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy 24:198-211, 2004
11. Ball RA, Kinchelow T: Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol 49:826-831, 2003
12. Hasson H, Danise A, Carini E, Bigoloni A, Galli A, Bonora S, Biswas P, Vecchi A, Lazzarin A, Castagna A: Increase in serum IgE levels during enfuvirtide treatment in multidrug-resistant HIV-1 infected patients. XV International AIDS Conference, July 11-16. Bangkok, Thailand, 2004:Abstract TuPeB4560
13. Jabara HH, Fu SM, Geha RS, Vercelli D: CD40 and IgE: Synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med 172:1861-1864, 1990
14. Jabara HH, Schneider LC, Shapira SK, Alfieri C, Moody CT, Kieff E, Geha RS, Vercelli D: Induction of germ-line and mature C epsilon transcripts in human B cells stimulated with rIL-4 and EBV. J Immunol 145:3468-3473, 1990
15. Kohl C, Debelic M: In vitro screening for inhalant allergy with multi SX 1 RAST (Phadiatop). Allergy 46:245-250, 1991
16. Casali P, Burastero SE, Nakamura M, Inghirami G, Notkins AL: Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1 + B-cell subset. Science 236:77-81, 1987
17. Burastero SE, Lo Pinto G, Goletti D, Cutolo M, Burlando L, Falagiani P: Rheumatoid arthritis with monoclonal IgE rheumatoid factor. J Rheumatol 20:489-494, 1993
18. Zhang L, Carruthers CD, He T, Huang Y, Cao Y, Wang G, Hahn B, Ho DD: HIV type 1 subtypes, coreceptor usage, and CCR5 polymorphism. AIDS Res Hum Retrovir 13:1357-1366, 1997
19. Vercelli D: Novel insights into class switch recombination. Curr Opin Allergy Clin Immunol 2:147-151, 2002
20. He B, Raab-Traub N, Casali P, Cerutti A: EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 171:5215-5224, 2003
21. Gauchat JP, Henchoz S, Mazzei G, Aubry JP, Brunner T, Blasey H, Life P, Talabot D, Flores-Romo L, Thompson J, et al.: Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 365:340-343, 1993
22. Burd PR, Thompson WC, Max EE, Mills FC: Activated mast cells produce interleukin 13. J Exp Med 181:1373-1380, 1995
23. Braun MC, Wang JM, Lahey E, Rabin RL, Kelsall BL: Activation of the formyl peptide receptor by the HIV-derived peptide T-20 suppresses interleukin-12 p70 production by human monocytes. Blood 97:3531-3536, 2001
24. Su SB, Gong WH, Gao JL, Shen WP, Grimm MC, Deng X, Murphy PM, Oppenheim JJ, Wang JM: T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor. Blood 93:3885-3892, 1999
25. Deng X, Ueda H, Su SB, Gong W, Dunlop NM, Gao JL, Murphy PM, Wang JM: A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R. Blood 94:1165-1173, 1999
26. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4:1302-1307, 1998
27. Romagnani S, Maggi E: Th1 versus Th2 responses in AIDS. Curr Opin Immunol 6:616-622, 1994
28. Romagnani S, Del Prete G, Manetti R, Ravina A, Annunziato F, De Carli M, Mazzetti M, Piccinni MP, D'Elios MM, Parronchi P, et al.: Role of TH1/TH2 cytokines in HIV infection. Immunol Rev 140:73-92, 1994
29. Maggi E, Mazzetti M, Ravina A, Annunziato F, de Carli M, Piccinni MP, Manetti R, Carbonari M, Pesce AM, del Prete G, et al.: Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. Science 265:244-248, 1994
30. Israel-Biet D, Labrousse F, Tourani JM, Sors H, Andrieu JM, Even P: Elevation of IgE in HIV-infected subjects: A marker of poor prognosis. J Allergy Clin Immunol 89:68-75, 1992
31. Vigano A, Principi N, Crupi L, Onorato J, Vincenzo ZG, Salvaggio A: Elevation of IgE in HIV-infected children and its correlation with the progression of disease. J Allergy Clin Immunol 95:627-632, 1995
32. Clerici M, Lucey DR, Berzofsky JA, Pinto LA, Wynn TA, Blatt SP, Dolan MJ, Hendrix CW, Wolf SF, Shearer GM: Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 262:1721-1724, 1993
33. Graziosi C, Pantaleo G, Gantt KR, Fortin JP, Demarest JF, Cohen OJ, Sekaly RP, Fauci AS: Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 265:248-252, 1994
34. Wild C, Dubay JW, Greenwell T, Baird T, Jr., Oas TG, McDanal C, Hunter E, Matthews T: Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci USA 91:12676-12680, 1994
35. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 91:9770-9774, 1994
36. Lawless MK, Barney S, Guthrie KI, Bucy TB, Petteway SR Jr., Merutka G: HIV-1 membrane fusion mechanism: Structural studies of the interactions between biologically-active peptides from gp41. Biochemistry 35:13697-13708, 1996